Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 1, 2006, Pages

  Zhu, Yujie ^a   Kyle, John W ^a   Lee, Peter J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Electrophysiology; Long QT syndrome; Sodium channel

Indexed keywords

BROMINE DERIVATIVE; FLECAINIDE; SODIUM CHANNEL;

ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG INACTIVATION; DRUG SENSITIVITY; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; MUTATIONAL ANALYSIS; PIPETTE; PRIORITY JOURNAL; PROTEIN INTERACTION; QT INTERVAL; STEADY STATE;

ANTI-ARRHYTHMIA AGENTS; CELL LINE; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLECAINIDE; HUMANS; ION CHANNEL GATING; KIDNEY; KINETICS; LONG QT SYNDROME; MEMBRANE POTENTIALS; MODELS, BIOLOGICAL; MUTAGENESIS, SITE-DIRECTED; MUTATION; SODIUM; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745726661     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01317.2005     Document Type: Article

References (35)

1. Abriel H, Wehrens XH, Benhorin J, Kerem B, and Kass RS. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation 102: 921-925, 2000.
2. An RH, Wang XL, Kerem B, Benhorin J, Medina A, Goldmit M, and Kass RS. Novel LQT-3 mutation affects Na+ channel activity through interactions between -α- and β1-subunits. Circ Res 83: 141-146, 1998.
3. Anno T and Hondeghem LM. Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ Res 66: 789-803, 1990.
4. Baroudi G and Chahine M. Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes. FEBS Lett 487: 224-228, 2000.
5. Benhorin J, Goldmit M, MacCluer JW, Blangero J, Goffen R, Leibovitch A, Rahat A, Wang Q, Medina A, Towbin J, and Kerem B. Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no 153. Online Hum Mutat 12: 72, 1998.
6. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, and Medina A. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 101: 1698-1706, 2000.
7. Chahine M, Deschenes I, Trottier E, Chen LQ, and Kallen RG. Restoration of fast inactivation in an inactivation-defective human heart sodium channel by the cysteine modifying reagent benzyl-MTS: analysis of IFM-ICM mutation. Biochem Biophys Res Commun 233: 606-610, 1997.
8. + channels. Physiol Rev 85: 33-47, 2005.
9. Gellens ME, George AL Jr, Chen LQ, Chahine M, Horn R, Barchi RL, and Kallen RG. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci USA 89: 554-558, 1992.
10. Grant AO, Chandra R, Keller C, Carboni M, and Starmer CF. Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. Biophys J 79: 3019-3035, 2000.
11. + channel inactivation gating. Circ Res 75: 114-122, 1994.
12. Kellenberger S, Scheuer T, and Catterall WA. Movement of the Na+ channel inactivation gate during inactivation. J Biol Chem 271: 30971-30979, 1996.
13. + channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol 121: 199-214, 2003.
14. + channels by flecainide: evidence from the analysis of disease-linked mutations. J Gen Physiol 120: 39-51, 2002.
15. Makielski JC, Ye B, Valdivia CR, Pagel MD, Pu J, Tester DJ, and Ackerman MJ. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res 93: 821-828, 2003.
16. Mantegazza M, Yu FH, Catterall WA, and Scheuer T. Role of the C-terminal domain in inactivation of brain and cardiac sodium channels. Proc Natl Acad Sci USA 98: 15348-15353, 2001.
17. + channel inactivation gate is a molecular complex: a novel role of the COOH-terminal domain. J Gen Physiol 123: 155-165, 2004.
18. Nagatomo T, Fan Z, Ye B, Tonkovich GS, January CT, Kyle JW, and Makielski JC. Temperature dependence of early and late currents in human cardiac wild-type and long Q-T ΔKPQ Na+ channels. Am J Physiol Heart Circ Physiol 275: H2016-H2024, 1998.
19. Ragsdale DS, McPhee JC, Scheuer T, and Catterall WA. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci USA 93: 9270-9275, 1996.
20. Ramos E and O'Leary ME. State-dependent trapping of flecainide in the cardiac sodium channel. J Physiol 560: 37-49, 2004.
21. Richmond JE, Featherstone DE, Hartmann HA, and Ruben PC. Slow inactivation in human cardiac sodium channels. Biophys J 74: 2945-2952, 1998.
22. Roden DM. Antiarrhythmic drugs. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. (10th ed.), edited by Hardman JG, Limbird LE, and Gilman AG. New York: McGraw-Hill, 2001, p. 933-970.
23. Sheets MF and Hanck DA. Charge immobilization of the voltage sensor in domain IV is independent of sodium current inactivation. J Physiol 563: 83-93, 2005.
24. Sheets MF, Kyle JW, Kallen RG, and Hanck DA. The Na channel voltage sensor associated with inactivation is localized to the external charged residues of domain IV, S4. Biophys J 77: 747-757, 1999.
25. Starmer CF and Grant AO. Phasic ion channel blockade. A kinetic model and parameter estimation procedure. Mol Pharmacol 28: 348-356, 1985.
26. Starmer CF, Grant AO, and Strauss HC. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J 46: 15-27, 1984.
27. Stauffer DA and Karlin A. Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates. Biochemistry 33: 6840-6849, 1994.
28. Tang MX, Redemann CT, and Szoka FC Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 7: 703-714, 1996.
29. Tateyama M, Rivolta I, Clancy CE, and Kass RS. Modulation of cardiac sodium channel gating by protein kinase A can be altered by disease-linked mutation. J Biol Chem 278: 46718-46726, 2003.
30. + channels. J Gen Physiol 113: 7-16, 1999.
31. Viswanathan PC, Bezzina CR, George AL Jr, Roden DM, Wilde AA, and Balser JR. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 104: 1200-1205, 2001.
32. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, and Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80: 805-811, 1995.
33. + channel α-subunit: a computational analysis. Circulation 102: 584-590, 2000.
34. +-channel inactivation. Proc Natl Acad Sci USA 89: 10910-10914, 1992.
35. Yang N, George AL Jr, and Horn R. Molecular basis of charge movement in voltage-gated sodium channels. Neuron 16: 113-122, 1996.